Results 141 to 150 of about 4,501 (180)

Pharmacokinetics of a Novel Diltiazem HCl Extended‐Release Tablet Formulation for Evening Administration

The Journal of Clinical Pharmacology, 2003
A novel diltiazem HCl extended‐release (ER) tablet formulation was developed for evening administration in the management of angina and hypertension. Pharmacokinetics of the formulation were evaluated to identify variations in morning (7 a.m. or 8 a.m.) versus evening (10 p.m.) drug administration.
Suryanarayana, Sista, John Chi-Keung, Lai, Okponanabofa, Eradiri, Kenneth S, Albert   +3 more
openaire   +2 more sources

Effect of solvent type on retardation properties of diltiazem HCl form liquisolid tablets

Colloids and Surfaces B: Biointerfaces, 2014
Liquisolid technique is a new approach to formulate sustained release dosage forms. It seems that the solubility of an active ingredient in solvent plays an important role in drug release profile. The aim of present study was to investigate the effect of solvent type on diltiazem hydrochloride release profile from liquisolid compacts.
Khosro, Adibkia, Javad, Shokri, Mohammad, Barzegar-Jalali, Mohammad, Solduzian, Yousef, Javadzadeh   +4 more
openaire   +2 more sources

A combination of nonionic surfactants and iontophoresis to enhance the transdermal drug delivery of ondansetron HCl and diltiazem HCl

European Journal of Pharmaceutics and Biopharmaceutics, 2012
The present work reports the evaluation of three nonionic ether-monohydroxyl surfactants (C(12)E(1), C(12)E(5,) and C(12)E(8)) as skin permeation enhancers in the transdermal drug delivery of two drugs: ondansetron hydrochloride and diltiazem hydrochloride, formulated as hydrogels. The enhancers are used alone, or in combination with iontophoresis (0.3
Sérgio M C, Silva, Longsheng, Hu, João J S, Sousa, Alberto A C C, Pais, Bozena B, Michniak-Kohn   +4 more
openaire   +2 more sources

Development of Modified Release Diltiazem HCl Tablets Using Composite Index to Identify Optimal Formulation

Drug Development and Industrial Pharmacy, 2003
This article reports the preparation of tartaric acid treated ispaghula husk powder for the development of modified release tablets of diltiazem HCl by adopting direct compression technique and a 32 full factorial design. The modified ispaghula husk powder showed superior swelling and gelling as compared to untreated powder.
M C, Gohel, M M, Patel, A F, Amin
openaire   +2 more sources

Rheological characterization of diltiazem HCl/cellulose wet masses using a mixer torque rheometer

International Journal of Pharmaceutics, 1998
Abstract The objective of the present investigations was to study the rheological behavior of wet powder masses containing two commonly used cellulose ethers, hydroxypropyl methylcellulose (HPMC) and hydroxyethyl cellulose (HEC), using a mixer torque rheometer.
Ramarao Chatlapalli, Bhagwan D. Rohera
openaire   +1 more source

[A comparison between diltiazem SR and diltiazem HCL in the treatment of angina pectoris].

Zhonghua nei ke za zhi, 1993
This study included 168 patients with angina pectoris, who were divided into two groups, the diltiazem SR (No. 88) group and diltiazem HCL (No. 80) group. The two groups were comparable in age and duration of coronary heart disease. The results were as follows: (1) The total clinical effect of diltiazem SR (94.3%) was slightly greater than that of ...
X S, Yang, Q L, Li, K, Rong
openaire   +1 more source

A Validated UV Spectroscopic method for Quantification of Lidocaine HCl and Diltiazem HCl

A Simple and routinely used UV- Spectroscopic technique has been developed for estimating Lidocaine hydrochloride and Diltiazem hydrochloride in bulk and combined dosage form. The simultaneous estimation using first- order derivative analysis was 0.1 M HCl solvent, with scanning at wavelengths of 223 nm and 250 nm for quantifying lidocaine HCl and ...
Nirali Chaudhari, Sanika Saskshee, Shruti Patel, Jay Chandwani, Heta Kachhiya   +4 more
openaire   +1 more source

Long-acting diltiazem HCL for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris

Expert Opinion on Pharmacotherapy, 2005
Hypertension is associated with increased cardio- and cerebrovascular morbidity and mortality; antihypertensive drugs have been shown to reduce the risk of adverse cardio- and cerebrovascular events. These events tend to be more common during the morning hours, a time when both normo- and hypertensives show a circadian peak in blood pressure (BP ...
Steven A, Claas, Stephen P, Glasser
openaire   +2 more sources

In vivo performance of controlled release pellets of diltiazem HCl.

Pakistan journal of pharmaceutical sciences, 2006
The test formulation of controlled release diltiazem pellets was evaluated in vivo, in comparison with Herbesser SR. Six healthy volunteers participated in the study, conducted according to a randomized, two-way crossover study design. The preparations were compared using the pharmacokinetic parameters plasma concentration-time curve (AUC(0- infinity)),
, Nisarur-ur-Rahman, Yuen, K H, Wong, Jia Woei   +2 more
openaire   +1 more source

FORMULATION AND IN VITRO EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF DILTIAZEM HCL

2023
The present study involves in the formulation and evaluation of Controlled release tablets of Diltiazem HCl (100mg). The objective of the present study was to formulate Diltiazem hcl Controlled release tablets by Direct compression method by using HPMC K 15M, HPC 2M and HEC 2M.
openaire   +1 more source